Hims & Hers Health (NYSE:HIMS) Given “Hold” Rating at Jefferies Financial Group

Hims & Hers Health (NYSE:HIMS)‘s stock had its “hold” rating reissued by research analysts at Jefferies Financial Group in a research note issued to investors on Tuesday, Marketbeat.com reports. They presently have a $15.00 price target on the stock, down from their previous price target of $17.00. Jefferies Financial Group’s target price points to a potential upside of 21.16% from the stock’s current price.

Several other research firms have also weighed in on HIMS. Piper Sandler boosted their price target on Hims & Hers Health from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 27th. Tigress Financial boosted their target price on Hims & Hers Health from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, January 5th. Truist Financial boosted their price target on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Guggenheim boosted their price target on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Finally, Canaccord Genuity Group initiated coverage on Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.85.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $12.38 on Tuesday. The business’s 50 day simple moving average is $13.42 and its 200 day simple moving average is $9.78. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16. The firm has a market cap of $2.65 billion, a PE ratio of -112.55 and a beta of 0.91.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same quarter last year, the firm earned ($0.05) EPS. Hims & Hers Health’s revenue for the quarter was up 47.4% compared to the same quarter last year. As a group, equities research analysts predict that Hims & Hers Health will post 0.1 EPS for the current year.

Insider Activity

In related news, CEO Andrew Dudum sold 15,100 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $9.01, for a total transaction of $136,051.00. Following the sale, the chief executive officer now owns 51,653 shares in the company, valued at approximately $465,393.53. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Hims & Hers Health news, CEO Andrew Dudum sold 15,100 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $9.01, for a total value of $136,051.00. Following the transaction, the chief executive officer now owns 51,653 shares in the company, valued at $465,393.53. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,503 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the completion of the transaction, the insider now owns 166,866 shares in the company, valued at approximately $2,611,452.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 675,838 shares of company stock valued at $8,487,125. Company insiders own 31.63% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Belpointe Asset Management LLC boosted its position in shares of Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after buying an additional 1,205 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Hims & Hers Health by 9.6% during the fourth quarter. Principal Financial Group Inc. now owns 14,130 shares of the company’s stock valued at $126,000 after buying an additional 1,234 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Hims & Hers Health by 29.1% during the second quarter. Osaic Holdings Inc. now owns 6,213 shares of the company’s stock valued at $58,000 after buying an additional 1,400 shares during the last quarter. Virtu Financial LLC boosted its position in shares of Hims & Hers Health by 8.4% during the fourth quarter. Virtu Financial LLC now owns 18,441 shares of the company’s stock valued at $118,000 after buying an additional 1,430 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Hims & Hers Health by 5.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after acquiring an additional 1,561 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.